Effective Jan. 1, UTU members taking certain brand-name drugs will be required to pay more for them unless they switch to generic or preferred versions.
Members who choose to stay on the non-formulary/non-preferred drug will be subject to the non-formulary/non-preferred copay.
If you are using one of the drugs noted below, contact your physician and request a prescription for one of the preferred alternatives to avoid paying the higher price.
A mailing will occur on Dec. 1 to members affected by this change.
These formulary changes are made quarterly.
The preferred alternative to Activella (0.5-0.1 mg) is estradiol-norethindrone acet (1-0.5 mg), Prempro or Premphase.
The preferred alternative to Alamast is cromolyn sodium, Patanol or Optivar.
The preferred alternative to Altace is ramipril capsules.
The preferred alternative to Ambien CR is zolpidem tartrate IR (generic Ambien)
The preferred alternative to Cimzia is Humira, Enbrel or Remicade.
The preferred alternative to Ertaczo is econazole nitrate, ketoconazole or nystatin.
The preferred alternative to Lorabid is cefdinir.
The preferred alternative to Ortho Tri-Cyclen Lo is Trinessa, Tri-Previfem or Tri-Sprintec.
The preferred alternative to Quixin is ciprofloxacin, tobramycin sulfate, Zymar, Vigamox or Iquix.
The preferred alternative to Retin-A Micro is tretinoin gel.
The preferred alternative to Retin-A Micro Pump is tretinoin gel.
- ERMA lifetime maximum benefit to increase in 2023
- RRB: Credit for military service under the Railroad Retirement Act
- 2022 Tentative Agreement ratification results and next steps
- Balloting closes TONIGHT for tentative national rail agreement
- A message to veterans from President Ferguson
- Important update for all SMART-TD and BLET members included in national negotiations
- Update on SMART-TD balloting for National Rail Tentative Agreement
- VSTD premium reset and benefit changes announced
- Appearances with federal officials reinforce that union is labor leader in Kansas
- Branson, Mo., TD Regional Training Seminar hotel deadline now Oct. 28